01:12 , Aug 19, 2017 |  BioCentury  |  Product Development

Restoring dependence

Netris Pharma S.A.S. is aiming to boost rates and durations of responses to immunotherapies by targeting a population of slow-growing cells these therapies leave behind. The biotech’s mAbs restore the pro-apoptotic function of dependence receptors,...
07:00 , May 7, 2015 |  BC Innovations  |  Translation in Brief

NYU cuts to the bone with MRCT

New York University School of Medicine expects its recent deal with the not-for-profit MRC Technology will help the university extract more value from its therapeutic targets than if it had partnered them with a biotech...
07:00 , Mar 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Netrin 1 (NTN1); unc-5 homolog B (UNC5B; UNC5H2) Human sample and mouse studies suggest inhibiting NTN1 or UNC5B could help treat obesity...
08:00 , Feb 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/ marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Netrin 1 (NTN1); unc-5 homolog A (Caenorhabditis elegans) (UNC5A; UNC5H1); UNC5B (UNC5H2) Studies in primary...